The fluorinated MUC1 glycopeptide-TTox conjugate 18b was successfully applied to immunizations of mice leading to strong tolerance-breaking immune responses and the production of selective IgG antibodies capable of binding to the native MUC1 antigen structures present on MCF-7 human breast cancer cells. This evidence concerns the gene MUC1 and breast carcinoma.